A Randomized, Double-Blind, Placebo-Controlled, Short-Term Monotherapy Study of MK-6186, an HIV-1 Non-Nucleoside...

Area of Science:

• Virology
• Pharmacology
• Clinical Medicine

Background:

• Human Immunodeficiency Virus type 1 (HIV-1) infection remains a global health challenge.
• Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are a crucial class of antiretroviral drugs.
• Development of novel NNRTIs with improved efficacy and resistance profiles is ongoing.

Purpose of the Study:

• To evaluate the antiviral activity, pharmacokinetics, and safety of MK-6186 in treatment-naïve HIV-1 infected males.
• To assess the efficacy of MK-6186 monotherapy in reducing viral load.
• To investigate the potential for resistance development with MK-6186 treatment.

Main Methods:

• A double-blind, randomized, two-panel study was conducted.
• Participants received MK-6186 (40 mg or 150 mg) or placebo daily for 7 days.
• Plasma HIV-1 RNA levels and MK-6186 pharmacokinetics were measured.

Main Results:

• MK-6186 demonstrated significant reductions in HIV-1 RNA levels compared to placebo.
• The 40 mg dose showed maximal antiviral activity.
• One participant on 150 mg experienced viral rebound associated with the V106A resistance mutation.

Conclusions:

• MK-6186 exhibits potent antiviral activity and favorable pharmacokinetics.
• The 40 mg dose appears optimal for monotherapy, while the 150 mg dose carries a risk of resistance.
• MK-6186 may be a valuable NNRTI for combination antiretroviral therapy to prevent resistance.